---
title: Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid
  leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature
  correlates with response
date: '2023-08-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37539479/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230804180814&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic
  cell transplantation (allo-HCT) is often driven by immune-related mechanisms and
  associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating
  agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data
  about using this combination regimen after allo-HCT are limited. We conducted a
  prospective, phase II, open-label, single-arm study in which we treated patients
  ...
disable_comments: true
---
Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients ...